Paralisis unilateral de cuerda vocal como manifestacion inicial de poliangitis microscopica grave.
Anti-neutrophil cytoplasmic antibodies (ANCA) are autoantibodies specific for antigens located in the cytoplasmic granules of neutrophils and lysosomes of monocytes. The ANCA-associated vasculitides (AAV) are multisystem diseases associated with autoantibodies that target myeloperoxidase (MPO-ANCA) and proteinase 3 (PR3-ANCA) (1). The major clinicopathologic variants of AAV are microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA), and eosinophilic granulomatosis with polyangiitis (EGPA) (1).
Microscopic polyangiitis is a necrotizing vasculitis, with few or no immune deposits, predominantly affecting small vessels, i.e., capillaries, venules, or arterioles. Granulomatous inflammation is absent, differentiating it from GPA (1). Patients typically present with fever, arthralgias or weight loss (61-78%), cutaneous manifestations (30-62%, mostly leukocytoclastic angiitis), peripheral neuropathy (37-72%), pulmonary disease (25-55%, capillaritis reported in 12-55%) and most importantly, renal involvement, characterized by crescentic necrotizing glomerulonephritis (80-100%) (2). Ear, nose and throat (ENT) symptoms are not common in MPA, and sometimes have been erroneously considered as an exclusive manifestation of GPA. ENT involvement may be an early sign of AAV; its presence has been associated with preserved renal function at disease onset, better long-term prognosis and improved survival (1).
Here, we present a MPA case with sole laryngeal involvement as initial manifestation, that later progressed to severe disease with rapidly progressive glomerulonephritis.
A 16 year-old female with a six-months history of dry cough and dyspnea was previously treated elsewhere with suspicion of infection, gastroesophageal reflux disease, asthma and allergy without improvement after several treatments. On arrival to our centre, these causes were sought and thoroughly discarded. The past medical history and physical examination were unremarkable. A fibronasolaryngoscopy showed arythenoidal and vocal cord edema (ventricular bands) with incomplete left vocal cord abduction.
Diagnostic investigation for vocal cord paralysis included a head, neck and chest CT scan, excluding lymphadenopathy, malignancy or aneurysms. Flexible bronchoscopy did not show any lesions suspicious of neoplastic or granulomatous origin. There was no clinical evidence of degenerative neural disorders. The patient had no history of thoracic surgery, previous endotracheal intubation or cervical traumatisms. As airway disease is a well-described feature of GPA, ANCA by both methods (indirect immunofluorescence and antigen-specific ELISA, both by Euroimmun AG, Lubeck, Germany) were performed, with the following results: P-ANCA 1:20, MPO-ANCA 128 U/mL (normal <20), negative PR3-ANCA. Other relevant laboratory tests included serum creatinine (S-Cr) 0.73 mg/dL (64.5 [micro]mol/L), C-reactive protein (C-RP) 1.22 mg/dL (normal <0.8), and haemoglobin (Hb) 12.7 g/dL. After careful search of potential conditions that could have explained her main symptoms, and in the absence of systemic involvement, the patient was labeled as having an "MPO-ANCA positive isolated vocal cord paralysis" and was sent to vocal rehabilitation with regular follow-up. Five months later, she presented with one-week history of vomit and distal legs edema; she was pale, with normal blood pressure, S-Cr 10.6 mg/dL (937 [micro]mol/L), C-RP 5.88 mg/dL, Hb 9.7 g/dL. Urine sediment showed countless dysmorphic erythrocytes and granular casts. With the suspicion of acute kidney involvement associated with her MPO-ANCA positive status, treatment was started with 1 g methylprednisolone pulses, IV-cyclophosphamide (IV-CYC) (400 mg), hemodialysis and plasmapheresis, the latter stopped after 5 exchanges when renal biopsy showed pauciimmune necrotizing glomerulonephritis with global sclerosis in 90% of glomerulii. IV-CYC was continued monthly until complete remission (6x 400 mg pulses). Glucocorticoids were tapered until withdrawal and she remained in remission with azathioprine 50 mg qd and hemodialysis 3 times/week. Three years after the onset of renal failure, she received a renal graft (cadaveric donor) with optimal results. She is currently asymptomatic; S-Cr is 0.88 mg/dL (77.8 [micro]mol/L), with normal urinalysis, blood cell count and acute phase reactants. She takes tacrolimus 3 mg bid, mycophenolate mofetil 500 mg tid and prednisone 5 mg qd. She improved after vocal rehabilitation and immunosuppressive treatment, with mild vocal cord paralysis as sequelae. The absence of granulomatous inflammation or other surrogate markers of GPA in addition to the presence of MPO-ANCA led us to establish MPA as the final diagnosis in this case.
Ear, nose and throat involvement is uncommon in MPA, described in 2-20% of patients in large series (2-4). These abnormalities accompany other disease manifestations at onset (16% of cases) or during relapses (3%) (2-5). They include sinusitis (6-9%), epistaxis (6-15%), unspecific rhinitis, polyps, sore throat (9-15%), mouth ulcers (21%) and deafness due to inner ear involvement (3%) (2-4). These otorhinolaryngological manifestations are usually mild, which contrast with the severe, infiltrative, and destructive nature of lesions usually observed in GPA.
Two similar previous cases have been reported. In the first, as part of a series of 30 MPA patients, unspecified ENT involvement progressed to severe pulmonary-renal disease within two years (6). The second was a 74 years-old woman with granulomas in the vocal cords as initial manifestation of GPA. The disease did not evolve into systemic form (7). Vocal cord paralysis has also been reported in polyarteritis nodosa, Behcet's disease, rheumatoid arthritis and eosinophilic granulomatosis with polyangiitis, although never as an initial isolated manifestation (8,9). In these cases, as in ours, glucocorticoid administration improved vocal cord function.
Why our patient progressed from isolated laryngeal involvement to severe full-blown vasculitis is unknown. MPA may present acutely, with life-threatening manifestations associated with widespread multisystemic disease or may have an indolent course that lasts for weeks to months without evidence of specific organ involvement. In previous series, the interval between initial symptoms and MPA diagnosis ranged between 14 days to 7.46 years, with an average of 3.7 months to 2.6 years (10,11). This long lapse clearly illustrates the difficulty faced in recognizing MPA, particularly when disease onset includes solely constitutional symptoms, upper respiratory tract disease, or single-organ involvement (2,7). Regarding the latter, a renal-limited form of AAV, typically associated with MPO ANCA and characterized by the absence of general symptoms and extrarenal vasculitis is usually considered part of the MPA spectrum, as its histopathologic features are indistinguishable from those found in systemic widespread MPA12. Some patients who initially have this limited form may subsequently develop full-blown, more easily identifiable MPA11.
As discrimination between major clinicopathological variants of AAV (GPA, MPA, EGPA) may be difficult, classification based in autoantibody specificity has been proposed. Categorization of cases as MPO-ANCA or PR3-ANCA seems to predict more accurately the response to therapy, long-term outcome, or relapse propensity rather than the clinical phenotypes of MPA or GPA13. In this sense, our patient may be suffering from a MPO-ANCAassociated vasculitis with ENT and renal disease.
Finally, although the link between vocal cord paralysis and the occurrence 11 months later of severe MPO-ANCA disease cannot be definitively established as causal, the lack of evidence for an alternative origin of the laryngeal disease, the presence of MPO-ANCA from the start, the improvement associated with glucocorticoids and immunosuppressants, and the long-term follow-up confirming the diagnosis of MPA, lead us to believe that the most likely explanation of the cordal paralysis was related to involvement of the recurrent laryngeal nerve by MPA.
To our best knowledge, this is the first case presenting with isolated vocal cord paralysis as initial manifestation of severe MPO-ANCA positive systemic vasculitis. In absence of more common causes of laryngeal disease, an unexplained etiology and the presence of positive ANCA testing, regular clinical and laboratory follow-up is advised in order to detect early, non-respiratory tract, serious and potentially irreversible organ involvement.
Received: 06 November 2016
Revised: 16 January 2017
Accepted: 14 March 2017
Conflict of interest:
The authors declare there are no conflicts of interest pertaining this work
(1.) Rahmattulla C, de Lind van Wijngaarden RA, Berden AE, Hauer HA, Flossmann O, Jayne DR, et al. Renal function and ear, nose, throat involvement in anti-neutrophil cytoplasmic antibodyassociated vasculitis: prospective data from the European Vasculitis Society clinical trials. Rheumatology (Oxford). 2015; 54(5): 899-907.
(2.) Guillevin L, Durand-Gasselin B, Cevallos R, Gayraud M, Lhote F, Callard P, et al. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum. 1999; 42(3): 421-30.
(3.) Savage CO, Winearls CG, Evans DJ, Rees AJ, Lockwood CM. Microscopic polyarteritis: presentation, pathology and prognosis. Q J Med. 1985; 56(220): 467-83.
(4.) Lhote F, Cohen P, Guillevin L. Polyarteritis nodosa, microscopic polyangiitis and Churg-Strauss syndrome. Lupus. 1998; 7(4): 238-58.
(5.) Lane SE, Watts RA, Shepstone L, Scott DG. Primary systemic vasculitis: clinical features and mortality. QJM. 2005; 98(2): 97-111.
(6.) Nakabayashi K, Arimura Y, Yoshihara K, Fukuoka T, Karube M, Yamato T, et al. Classification of clinical subtypes, patient survival, kidney prognosis, and relapse in patients with MPO-ANCAassociated vasculitis: a single-center experience. Mod Rheumatol. 2009; 19(4):420-6.
(7.) Grijalba UM, Lopez CA, Medina SJJ, Saiz CMA. Isolated laryngeal involvement as the first manifestation of Wegener's disease. A case report. Acta Otorrinolaringol Esp. 1997; 48(3):239-41.
(8.) Mazzantini M, Fattori B, Matteucci F, Gaeta P, Ursino F. Neurolaryngeal involvement in Churg-Strauss syndrome. Eur Arch Otorhinolaryngol. 1998; 255(6):302-6.
(9.) Kashihara K, Ishizu H, Shomori T, Iwane H, Ota H. Avellis syndrome in systemic rheumatoid vasculitis. Rinsho Shinkeigaku. 1995; 35(10):1155-9.
(10.) Agard C, Mouthon L, Mahr A, Guillevin L. Microscopic polyangiitis and polyarteritis nodosa: how and when do they start? Arthritis Rheum. 2003; 49(5):709-15.
(11.) Poulton CJ, Nachman PH, Hu Y, McGregor JG, Jennette JC, Falk RJ, et al. Pathways to renal biopsy and diagnosis among patients with ANCA small-vessel vasculitis. Clin Exp Rheumatol. 2013; 31(1 Suppl 75):S32-7.
(12.) Hauer HA, Bajema IM, van Houwelingen HC, Ferrario F, Noel LH, Waldherr R, et al. Renal histology in ANCA-associated vasculitis: differences between diagnostic and serologic subgroups. Kidney Int. 2002; 61(1):80-9.
(13.) Lionaki S, Blyth ER, Hogan SL, Hu Y, Senior BA, Jennette CE, et al. Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum. 2012; 64(10):3452-62.
Luis Felipe Flores-Suarez, Marco Antonio Alba, Gabriel Tona
Instituto Nacional de Enfermedades Respiratorias, Ciudad Mexico, Mexico.
Luis Felipe Flores-Suarez. Calz. Tlalpan No. 4502, Col. Seccion XVI, Deleg. Tlalpan, Distrito Federal CP. 14080, Mexico. Phone: +52 55 5487 1700. E-mail: email@example.com.
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Case report|
|Author:||Felipe Flores-Suarez, Luis; Antonio Alba, Marco; Tona, Gabriel|
|Date:||Jan 1, 2017|
|Previous Article:||Propiedades metricas del "timed get up and go version modificada" en el riesgo de caidas en mujeres activas.|
|Next Article:||?Es Colombia un pais violento?|